Vaxcyte, Inc. (PCVX) Financial Statements (2026 and earlier)

Company Profile

Business Address 825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,747,208,0001,080,227,000931,376,000245,970,000386,200,000
Cash and cash equivalent387,878,000397,451,000834,657,00068,985,000386,200,000
Short-term investments1,359,330,000682,776,00096,719,000176,985,000 
Receivables 20,262,0003,607,000   
Prepaid expense 15,732,0006,159,000   
Other current assets 4,456,0002,105,000   
Other undisclosed current assets327,0003,856,00011,179,00010,378,0002,804,000
Total current assets:1,787,985,0001,095,954,000942,555,000256,348,000389,004,000
Noncurrent Assets
Operating lease, right-of-use asset72,102,00030,997,00021,288,00027,958,000 
Property, plant and equipment198,045,00079,626,00010,360,0007,954,0003,272,000
Long-term investments and receivables1,387,510,000162,675,00026,549,00027,117,000 
Long-term investments1,387,510,000162,675,00026,549,00027,117,000 
Restricted cash and investments1,317,0001,103,000871,000871,000 
Other noncurrent assets64,359,00037,562,0004,555,0004,089,000550,000
Total noncurrent assets:1,723,333,000311,963,00063,623,00067,989,0003,822,000
TOTAL ASSETS:3,511,318,0001,407,917,0001,006,178,000324,337,000392,826,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities77,575,00074,402,00025,170,00019,000,00033,835,000
Employee-related liabilities3,455,000284,000
Accounts payable48,452,00014,587,0009,795,0006,758,00029,785,000
Accrued liabilities29,123,00059,815,00015,375,0008,787,0003,766,000
Deferred rent credit     14,000
Due to related parties  677,000
Other undisclosed current liabilities62,605,00070,936,00015,355,0009,716,00012,335,000
Total current liabilities:140,180,000145,338,00040,525,00028,716,00046,861,000
Noncurrent Liabilities
Long-term debt and lease obligation:    11,507,000 
Liabilities, other than long-term debt65,319,00022,111,00012,040,00096,000122,000
Deferred rent credit     10,000
Other liabilities 100,000 9,00096,000112,000
Operating lease, liability65,219,00022,111,00012,031,00011,507,000 
Total noncurrent liabilities:65,319,00022,111,00012,040,00011,603,000122,000
Total liabilities:205,499,000167,449,00052,565,00040,319,00046,983,000
Equity
Equity, attributable to parent3,305,819,0001,240,468,000953,613,000284,018,000345,843,000
Common stock128,00098,00082,00056,00054,000
Additional paid in capital4,697,883,0002,164,583,0001,476,018,000582,844,000544,353,000
Accumulated other comprehensive income (loss)(3,873,000)179,000(361,000)(241,000) 
Accumulated deficit(1,388,319,000)(924,392,000)(522,126,000)(298,641,000)(198,564,000)
Total equity:3,305,819,0001,240,468,000953,613,000284,018,000345,843,000
TOTAL LIABILITIES AND EQUITY:3,511,318,0001,407,917,0001,006,178,000324,337,000392,826,000

Income Statement (P&L) (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(569,546,000)(468,041,000)(232,256,000)(103,670,000)(89,581,000)
Other undisclosed operating income 4,375,000    
Operating loss:(569,546,000)(468,041,000)(232,256,000)(103,670,000)(89,581,000)
Nonoperating income (expense)105,619,00065,775,0008,771,0005,606,000(1,743,000)
Investment income, nonoperating   344,000244,000
Gain (loss), foreign currency transaction, before tax    1,669,000(2,351,000)
Other nonoperating income105,619,00065,775,0008,771,0003,593,000364,000
Interest and debt expense   (2,000)(7,000)(7,000)
Loss from continuing operations:(463,927,000)(402,266,000)(223,487,000)(98,071,000)(91,331,000)
Loss before gain (loss) on sale of properties:(98,071,000)(91,331,000)
Other undisclosed net income (loss)   2,000(2,006,000)2,114,000
Net loss available to common stockholders, diluted:(463,927,000)(402,266,000)(223,485,000)(100,077,000)(89,217,000)

Comprehensive Income (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(463,927,000)(402,266,000)(223,485,000)(100,077,000)(89,217,000)
Comprehensive loss:(463,927,000)(402,266,000)(223,485,000)(100,077,000)(89,217,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(4,052,000)540,000(120,000)(241,000) 
Comprehensive loss, net of tax, attributable to parent:(467,979,000)(401,726,000)(223,605,000)(100,318,000)(89,217,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: